ARAP1 and serous adenocarcinoma: For example, Nadaraja et al. [15] confirmed that low expression of ARAP1 is an independent prognostic biomarker of shorter progression-free survival in older patients with ovarian high-grade serous adenocarcinoma being administered first-line platinum-based antineoplastic therapy.